Involvement of c-Src kinase in the regulation of TGF-β1-induced apoptosis
Transforming growth factor-β1 (TGF-β1) is a potent inducer of apoptosis in normal hepatocytes, and acquiring resistance to TGF-β1 may be a critical step in the development of hepatocellular carcinoma (HCC). In this study, we investigated the possible involvement of c-Src in the regulation of TGF-β1-...
Saved in:
Published in | Oncogene Vol. 23; no. 37; pp. 6272 - 6281 |
---|---|
Main Authors | , , , , , , , |
Format | Journal Article |
Language | English |
Published |
Basingstoke
Nature Publishing
19.08.2004
Nature Publishing Group |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | Transforming growth factor-β1 (TGF-β1) is a potent inducer of apoptosis in normal hepatocytes, and acquiring resistance to TGF-β1 may be a critical step in the development of hepatocellular carcinoma (HCC). In this study, we investigated the possible involvement of c-Src in the regulation of TGF-β1-induced apoptosis. TGF-β1 induced transient activation of c-Src and its subsequent caspase-mediated degradation concomitant with cell death in FaO hepatoma cells, which are sensitive to TGF-β1. In response to TGF-β1, activated c-Src was translocated into the cytoplasmic membrane, then relocated to the nuclei of apoptotic cells during its cleavage. In TGF-β1-induced apoptotic cells, c-Src maintained its tight association with p85 FAK fragment cleaved by caspases, possibly contributing to focal adhesion disassembly. TGF-β1-induced apoptosis was enhanced by either inhibition of c-Src activity using PP1 or PP2, or by overexpression of dominant-negative c-Src. In contrast, overexpression of constitutively active c-Src inhibited apoptosis suppressing TGF-β1-induced activation of p38, JNK and caspases. In many HCC cell lines resistant to TGF-β1, enhanced c-Src activity was detected. We hypothesize that activated c-Src in HCC may contribute to resistance against the apoptotic and/ or antiproliferative properties of TGF-β1. |
---|---|
ISSN: | 0950-9232 1476-5594 |
DOI: | 10.1038/sj.onc.1207856 |